


REMARKS

This is a response to the Office Action dated 05/16/03.

In view of the 112 rejection pertaining to scope of disclosure and claims, it is suggested that the newly added Claim 11 is commensurate with the scope of the disclosure.

In addition, the use of a combination of 2ME and eugenol is not believed to be suggested in the prior art.

Respectfully submitted,


David G. Henry
Registration No. 32,735
900 Washington Ave.
P.O. Box 1470
Waco, TX 76703-1470
(254) 755-4334
(254) 754-6331 (Fax)

BEST AVAILABLE COPY